Boryung Pharmaceutical won patent nullity suit with respect to the composition of 'Gleevec'
On Apr 11, Boryung Pharmaceutical won patent nullity suit with respect to the composition of 'Gleevec' (ingredient: imatinib mesylate)'s high-dose product against Novartis, and the Supreme Court ruled in favor of Boryung. As a result, the composition patent whose duration of a patent right was ti...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
